Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

223Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PET/CT versus standard imaging for prediction of survival in patients with recurrent head and neck squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reproducibility of MR-based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Behandling af tymom og thymuskarcinom

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Stomach interference in 82Rb-PET myocardial perfusion imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The aim of this study was to investigate the prognostic value of the quantitative assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who have advanced metastatic castration-resistant prostate cancer (mCRPC) and are receiving 223RaCl2 We hypothesized that the BSI can serve as a prognostic biomarker of overall survival (OS) and hematologic toxicity and as a tool for response assessment in patients with mCRPC treated with 223RaCl2Methods: This study was a retrospective investigation of a Danish cohort of mCRPC patients who received 223RaCl2 therapy between March 2014 and October 2015 and for whom baseline bone scintigraphy was available. Bone scintigraphy studies were reviewed and graded according to the extent of disease. Furthermore, an automated BSI (EXINI BoneBSI) was obtained for baseline scintigraphy studies and follow-up scans after 3 cycles as well as at the end of therapy. Clinical outcomes were OS and occurrence of hematologic toxicity of grades 2-5. Associations between the BSI and clinical outcomes were investigated in multivariate regression models including the visual assessment of bone scintigraphy and other relevant covariates. Results: A total of 88 patients were included. The median number of completed 223RaCl2 cycles was 4, and 27 patients (31%) completed 6 cycles. The BSI was significantly associated with OS in the multivariate analysis; the median OS for patients with a BSI of greater than 5 was 8.2 mo, and the median OS for patients with a BSI of less than or equal to 5 was 15.0 mo (hazard ratio, 2.65 [95% confidence interval, 1.5-4.71]; P = 0.001). Likewise, the baseline BSI was prognostic for the occurrence of hematologic toxicity; patients with a BSI of greater than 5 had an odds ratio of 3.02 (95% confidence interval, 1.2-7.8; P = 0.02) for toxicity. The BSI declined during therapy in 44% of the patients who completed 3 cycles of 223RaCl2 (n = 52) and in 84% of the patients after the end of therapy (n = 32). There was no significant association between a change in the BSI during therapy and OS. Conclusion: The BSI is a promising biomarker for prognostication of OS and hematologic toxicity in late-stage mCRPC patients receiving 223RaCl2 Further prospective studies are needed to evaluate the potential of the BSI for response assessment in 223RaCl2 therapy.

Original languageEnglish
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume59
Issue number4
Pages (from-to)596-602
Number of pages7
ISSN0161-5505
DOIs
Publication statusPublished - 2018

ID: 56301761